EVENTS | VIEW CALENDAR
Partnering up for sample prep
WEST BRIDGEWATER, Mass.—Pressure BioSciences Inc.(PBI) recently announced a collaboration agreement with Alfa Wassermann Proteomic Technologies, LLC (AWPT) to co-develop sample preparation methods to enrich for low abundance proteins and sub-cellular complexes from cells and tissues utilizing PBI's Pressure Cycling Technology (PCT) and AWPT's AW Promatix 1000. Financial Terms of the collaboration were not disclosed.
The collaboration is intended to last for three months and can be extended by mutual consent. Intellectual property developed will be co-owned, and there is an agreement to cross-license new intellectual property to allow each company to have a worldwide, exclusive, royalty free license in their area of focus – PCT sample preparation for PBI and post-extraction protein processing for AWPT.
"The three month evaluation involves PBI and AWPT working together to analyze sample preparation processes and organelle integrity," says Dino DiCamillo, president, AWPT. "It is an opportunity for AWPT to gain experience with the PCT Sample Preparation System (PCT SPS) in-house and for PBI to investigate the quality of the fractions collected from the AW Promatix 1000. The collaboration is for "proof-of-principle," which we expect can be accomplished in about three months; however, if a longer period of evaluation is needed, the agreement can be extended by mutual consent. We expect that product development will follow successful proof-of-principle, but this phase of the relationship is not covered under the current collaboration agreement."
According to DiCamillo, the PBI technology brings robustness and reproducibility to the tissue and cell processing aspect of sample preparation and the Promatix 1000 brings automated, enriched and fractionated organelles and macromolecular complexes to the researcher. Together the two processes reduce the amount of time, enhance reproducibility and increase productivity for low abundance proteomics, cell transport and drug metabolism research. This should have impact in basic research, metabolic disorders and drug discovery research.
Richard T. Schumacher, Founder, President, and CEO of Pressure BioSciences, comments: "Having ready access to the AWPT technology will be beneficial to our scientists as they continue the development of front-end, proteomic extraction methods for state-of-the-art, downstream instrumentation. We hope that the combination of the PCT Sample Preparation System with the AW Promatix 1000 will result in an elegant and compelling platform for the enrichment of low abundance proteins and sub-cellular complexes, bio-molecules that many believe are essential to the development of a better understanding of human disease."
DiCamillo adds: "The proposed research plan is focused on the development of PCT-based lysis methods suitable for the isolation of intact sub-cellular complexes, including organelles. We expect such methods will help to maximize the performance of our flagship product, the AW Promatix 1000—a novel instrument that automates the separation, fractionation, and enrichment of sub-cellular particles." The collaborators expect that pressure cycling technology will enhance the sample preparation aspect over most traditional methods allowing the AW Promatix 1000 to produce highly reproducible fractions for researchers. It is hoped that the PBI PCT sample preparation system will offer more reliable, reproducible, rapid, controllable, and safe extraction, compared to current methods. Studies pioneered by Pressure BioSciences, Inc. (PBI) (formerly known as Boston Biomedica, Inc.) have shown that the rapid, alternating application of high pressure to biological molecules can result in more rapid, reproducible, and safe processing, which can be finely controlled by modulating the pressure, temperature, and number or pressure cycles.